Mannosyltransferase is one of the enzymes involved in the synthesis of glycosylphosphatidylinositol (GPI) anchor, which catalyzes the transfer of glucose to the mannose residue in the GPI structure. It mainly includes three types of enzymes.
The synergistic effect of these three enzymes ensures that GPI-anchored proteins are synthesized correctly so that they are positioned on the cell membrane. Based on this mechanism, CD BioGlyco provides specialized mannosyltransferase inhibitor development services, which help provide new strategies and approaches for the research of various diseases.
Our research team conducts basic structural research on mannosyltransferase through X-ray crystallography, nuclear magnetic resonance, and other techniques, they master the structure of mannosyltransferase as well as its substrate binding site and reaction mechanism, which is an important basis for the development of inhibitors. We offer a diverse approach to mannosyltransferase inhibitor development.
CD BioGlyco further chemically modifies and optimizes the structure of the candidate mannosyltransferase inhibitors obtained through preliminary screening to enhance their selectivity, affinity, and pharmacokinetic properties. We perform efficient synthesis, purification, and characterization based on optimized inhibitor structures.
CD BioGlyco provides skilled activity assessment services such as enzyme activity measurement, cell experiments, and animal model research. Through in vitro and in vivo experiments, we evaluate the impact of inhibitors on the activity of the target mannosyltransferase and determine its efficacy and mechanism.
Fig.1 Mannosyltransferase inhibitor development service. (CD BioGlyco)
Technology: Thin-layer chromatography
Journal: The EMBO Journal
Results: The authors used a screening approach to find natural compound inhibitors of GPI-anchored synthesis in yeast and identified YW3548, a terpene lactone that blocked the incorporation of a third mannose into the intermediate structure of GPI. The authors analyzed the effect of YW3548 on in vitro GPI synthesis in S. cerevisiae (A), P. falciparum (B), and T. brucei (C). The results indicated that YW3548 blocked GPI synthesis in yeast and mammalian cells, but not in protozoa, indicating that there were significant interspecies differences in GPI synthesis.
Fig.2 The role of YW3548 in protozoan systems. (Sütterlin, et al., 1997)
CD BioGlyco provides high-quality and efficient mannosyltransferase inhibitor development service, and we have effective project management capabilities to ensure results are delivered on time and meet client's requirements. Please feel free to contact us if you would like to acquire detailed development information.